APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages

Virology

Volumn 379, Issue 2, 2008, Pages 266-274

  Miyagi, Eri ^a   Schwartzkopff, Franziska ^b   Plishka, Ronald ^a   Buckler White, Alicia ^a   Clouse, Kathleen A ^b   Strebel, Klaus ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

APOBEC3G; HIV 1; Macrophages; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G;

ARTICLE; CELL DIFFERENTIATION; CELL FREE SYSTEM; CONTROLLED STUDY; GENE MUTATION; GENOME; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; VIRION; VIRUS GENE; VIRUS INFECTION; VIRUS REPLICATION;

BASE SEQUENCE; CELL DIFFERENTIATION; CELLS, CULTURED; CYTIDINE DEAMINASE; DNA PRIMERS; DNA, VIRAL; DOWN-REGULATION; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOME, VIRAL; HIV-1; HUMANS; MACROPHAGES; MUTATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRULENCE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 50349100094     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.06.033     Document Type: Article

References (47)

1. Agrawal L., Vanhorn-Ali Z., and Alkhatib G. Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs). J. Leukoc. Biol. 72 (2002) 1063-1074
2. Akari H., Fujita M., Kao S., Khan M.A., Shehu-Xhilaga M., Adachi A., and Strebel K. High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. J. Biol. Chem. 279 (2004) 12355-12362
3. Bishop K.N., Holmes R.K., and Malim M.H. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80 (2006) 8450-8458
4. Chowdhury I.H., Chao W., Potash M.J., Sova P., Gendelman H.E., and Volsky D.J. vif-negative human immunodeficiency virus type 1 persistently replicates in primary macrophages, producing attenuated progeny virus. J. Virol. 70 (1996) 5336-5345
5. Conticello S.G., Harris R.S., and Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13 (2003) 2009-2013
6. Cota M., Mengozzi M., Vicenzi E., Panina-Bordignon P., Sinigaglia F., Transidico P., Sozzani S., Mantovani A., and Poli G. Selective inhibition of HIV replication in primary macrophages but not T lymphocytes by macrophage-derived chemokine. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9162-9167
7. Fisher A.G., Ensoli B., Ivanoff L., Chamberlain M., Petteway S., Ratner L., Gallo R.C., and Wong-Staal F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237 (1987) 888-893
8. Gabuzda D.H., Li H., Lawrence K., Vasir B.S., Crawford K., and Langhoff E. Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. J. Acquir. Immune Defic. Syndr. 7 (1994) 908-915
9. Gessani S., Puddu P., Varano B., Borghi P., Conti L., Fantuzzi L., and Belardelli F. Induction of beta interferon by human immunodeficiency virus type 1 and its gp120 protein in human monocytes-macrophages: role of beta interferon in restriction of virus replication. J. Virol. 68 (1994) 1983-1986
10. Gruber M.F., Weih K.A., Boone E.J., Smith P.D., and Clouse K.A. Endogenous macrophage CSF production is associated with viral replication in HIV-1-infected human monocyte-derived macrophages. J. Immunol. 154 (1995) 5528-5535
11. Guo F., Cen S., Niu M., Saadatmand J., and Kleiman L. Inhibition of tRNA3Lys-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80 (2006) 11710-11722
12. Guo F., Cen S., Niu M., Yang Y., Gorelick R.J., and Kleiman L. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J. Virol. 81 (2007) 11322-11331
13. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., and Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 113 (2003) 803-809
14. Kao S., Goila-Gaur R., Miyagi E., Khan M.A., Opi S., Takeuchi H., and Strebel K. Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology 369 (2007) 329-339
15. Kao S., Khan M.A., Miyagi E., Plishka R., Buckler-White A., and Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77 (2003) 11398-11407
16. Kawamura M., Ishizaki T., Ishimoto A., Shioda T., Kitamura T., and Adachi A. Growth ability of human immunodeficiency virus type 1 auxiliary gene mutants in primary blood macrophage cultures. J. Gen. Virol. 75 Pt 9 (1994) 2427-2431
17. Khan M.A., Goila-Gaur R., Opi S., Miyagi E., Takeuchi H., Kao S., and Strebel K. Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 4 (2007) 48
18. Khan M.A., Kao S., Miyagi E., Takeuchi H., Goila-Gaur R., Opi S., Gipson C.L., Parslow T.G., Ly H., and Strebel K. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79 (2005) 5870-5874
19. Lecossier D., Bouchonnet F., Clavel F., and Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300 (2003) 1112
20. Liu B., Yu X., Luo K., Yu Y., and Yu X.F. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J. Virol. 78 (2004) 2072-2081
21. Luo K., Wang T., Liu B., Tian C., Xiao Z., Kappes J., and Yu X.F. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81 (2007) 7238-7248
22. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 (2003) 99-103
23. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., and Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114 (2003) 21-31
24. Marin M., Rose K.M., Kozak S.L., and Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9 (2003) 1398-1403
25. Mbisa J.L., Barr R., Thomas J.A., Vandegraaff N., Dorweiler I.J., Svarovskaia E.S., Brown W.L., Mansky L.M., Gorelick R.J., Harris R.S., Engelman A., and Pathak V.K. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81 (2007) 7099-7110
26. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., and Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279 (2004) 7792-7798
27. Meltzer M.S., Skillman D.R., Gomatos P.J., Kalter D.C., and Gendelman H.E. Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu. Rev. Immunol. 8 (1990) 169-194
28. Miyagi E., Opi S., Takeuchi H., Khan M., Goila-Gaur R., Kao S., and Strebel K. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81 (2007) 13346-13353
29. Moriuchi H., and Moriuchi M. Dichotomous effects of macrophage-derived chemokine on HIV infection. AIDS 13 (1999) 994-996
30. Newman E.N., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., and Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15 (2005) 166-170
31. Opi S., Kao S., Goila-Gaur R., Khan M.A., Miyagi E., Takeuchi H., and Strebel K. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol. 81 (2007) 8236-8246
32. Opi S., Takeuchi H., Kao S., Khan M.A., Miyagi E., Goila-Gaur R., Iwatani Y., Levin J.G., and Strebel K. Monomeric APOBEC3G is catalytically active and has antiviral activity. J. Virol. 80 (2006) 4673-4682
33. Pal R., Garzino-Demo A., Markham P.D., Burns J., Brown M., Gallo R.C., and DeVico A.L. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 278 (1997) 695-698
34. Peng G., Lei K.J., Jin W., Greenwell-Wild T., and Wahl S.M. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 203 (2006) 41-46
35. Schubert U., Clouse K.A., and Strebel K. Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J. Virol. 69 (1995) 7699-7711
36. Schumacher A.J., Hache G., Macduff D.A., Brown W.L., and Harris R.S. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 82 (2008) 2652-2660
37. Sheehy A.M., Gaddis N.C., and Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9 (2003) 1404-1407
38. Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K., and Uchiyama T. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 278 (2003) 44412-44416
39. Soros V.B., Yonemoto W., and Greene W.C. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3 (2007) e15
40. Stopak K., de Noronha C., Yonemoto W., and Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12 (2003) 591-601
41. Strebel K., Daugherty D., Clouse K., Cohen D., Folks T., and Martin M.A. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 328 (1987) 728-730
42. Struyf S., Proost P., Sozzani S., Mantovani A., Wuyts A., De Clercq E., Schols D., and Van Damme J. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J. Immunol. 161 (1998) 2672-2675
43. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46 (2002) 1896-1905
44. Willey R.L., Smith D.H., Lasky L.A., Theodore T.S., Earl P.L., Moss B., Capon D.J., and Martin M.A. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62 (1988) 139-147
45. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., and Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11 (2004) 435-442
46. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., and Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 (2003) 1056-1060
47. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., and Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424 (2003) 94-98